We have some exciting news to share! The Motley Fool UK has now become The Twelfth Magpie -- an independent, UK-owned company, led by our long-serving UK management team — Mark Rogers, Chris Nials and Heather Adlington. In practical terms, it’s the same team you know, now fully focused on serving our UK readers and members.

Just as importantly, our approach remains unchanged: long-term, jargon-free, and on your side. This site is our new home, and there will be extra tweaks made across the coming few days as we settle in. So if anything looks a little off, please bear with us!

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Could these two small-caps help you to retire early?

Edward Sheldon profiles two exciting companies at the smaller end of the market.

| More on:

You’re reading a free article with opinions that may differ from The Twelfth Magpie’s Premium Investing Services. Become a member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn more, and get a free 'Best Buy Now' stock!.

Small-cap shares can no doubt be volatile, yet the upside is that they can offer the potential for substantial capital gains. Today I’m running the rule over two small-caps that look like interesting opportunities.

Amino Technologies

The way we watch TV has changed dramatically in the last decade or so, and one company at the heart of this change is £140m market cap Amino Technologies (LSE: AMO).

Should you buy Amino Technologies plc shares today?

Before you decide, please take a moment to review this report first. Despite ongoing uncertainties from US tariffs to global conflicts, Mark Rogers and his team believe many UK shares still trade at substantial discounts, offering savvy investors plenty of potential opportunities to learn about.

That’s why this could be an ideal time to secure this valuable research – Mark’s analysts have scoured the markets to reveal 5 of his favourite long-term ‘Buys’. Please, don’t make any big decisions before seeing them.

Based in Cambridge, Amino is a global provider of digital TV entertainment and cloud solutions, and has developed a range of products and solutions designed to help broadband network operators deliver entertainment and associated connected home services to the consumer.

Shares in Amino have been on fire recently, gaining a huge 83% over the last 12 months. Can this share price momentum continue?

Amino reported excellent results in February, announcing that the successful integrations of two recent acquisitions had served to increase the company’s scale and helped to fuel strong revenue and profit growth over the past 12 months. Indeed, for the full year, revenue increased 80% to £75.2m, including organic revenue growth of 7%, adjusted profit before tax rose 96% to £10.2m, and the dividend was increased by 10% to 6.05p per share.

Management was upbeat about the future, stating that with a strong order book and an improved sales pipeline visibility for the first half of 2017, the company is looking forward to “further long-term sustainable profitable growth.”

Small-cap companies are often less researched than larger companies, and in Amino’s case, just three analysts cover the stock. Consensus earnings of 13.2p for FY2017 place the company on a forward looking P/E of just 14.8, an undemanding valuation for a fast-growing company operating in an exciting sector.

Amino also has dividend appeal, with last year’s payout of 6.05p equating to a yield of 3.1% at the current share price. It’s also worth noting that the company has increased its dividend every year for the last five years. 

Overall, Amino Technologies certainly looks like an attractive opportunity in the small-cap space and I believe the stock could offer further gains despite the recent share price momentum.

Alliance Pharmaceuticals

Another small-cap that looks interesting is £223m market cap Alliance Pharmaceuticals (LSE: APH), a company involved in the acquisition, marketing and distribution of pharmaceutical products.

After the acquisition of Sinclair Pharma‘s Healthcare Products business in 2015, sales and profits in 2016 were more than double the previous year, and the company now has significant geographical diversification, with sales being generated in over 100 countries. 

City analysts forecast earnings growth of 6.5% and 12% for the next two years, and management recently stated that “the current year has started well and we look forward to building on our foundations: an attractive, balanced portfolio, an expanded geographic footprint and a strong team.

The healthcare sector has considerable long-term investment potential to my mind, with ageing populations and on-going medical advances set to underpin the sector’s growth in the years ahead. And on a forward looking P/E ratio of just 11.5, with a dividend yield of 2.6%, Alliance Pharmaceuticals looks like a small-cap stock that warrants closer inspection.

Edward Sheldon has no position in any shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Rear view image depicting a senior man in his 70s sitting on a bench leading down to the iconic Seven Sisters cliffs on the coastline of East Sussex, UK. The man is wearing casual clothing - blue denim jeans, a red checked shirt, navy blue gilet. The man is having a rest from hiking and his hiking pole is leaning up against the bench.
Investing Articles

Up 1,146%! 7 things I’ve learned from the stunning Rolls-Royce share price comeback 

Harvey Jones has made a fair bit of money out of the booming Rolls-Royce share price, but he's also learned…

Read more »

Golden Retirees Heading to Beach
Investing Articles

4 steps to building a £38,456 retirement income with ISA shares

Investing £300 a month could deliver a life-changing cash stream in retirement with high-yield income shares. Royston Wild explains how.

Read more »

Content white businesswoman being congratulated by colleagues at her retirement party
Investing Articles

How investing in a Cash ISA could cost you a comfortable retirement

Cash ISAs are celebrated for the brilliant tax benefits they provide. But could focusing on them cost savers the chance…

Read more »

Young black woman in a wheelchair working online from home
Investing Articles

How much could Barclays shares pay in dividends by 2028?

Barclays is one of the FTSE 100's most popular dividend shares. How much could they provide over the next three…

Read more »

Investor looking at stock graph on a tablet with their finger hovering over the Buy button
Investing Articles

With a 6% yield and a P/E of just 7.4, is this share a screaming buy for a second income?

Mark Hartley looks at the second income potential of a popular UK dividend stock that still looks undervalued despite compelling…

Read more »

Investing Articles

Forget Nvidia! This ETF is booming inside my Stocks and Shares ISA

A thematic ETF inside this writer's ISA has more doubled the return of Nvidia stock so far in 2026. But…

Read more »

Shot of an young mixed-race woman using her cellphone while out cycling through the city
Investing Articles

These cheap FTSE 250 shares could deliver a £1,550 ISA income in just 12 months!

Searching for the best low-cost dividend stocks to buy? Royston Wild reveals two FTSE 250 property shares with yields above…

Read more »

Landlady greets regular at real ale pub
Investing Articles

How much in dividends will these high-yield shares generate in 2026?

With 9.5% and 8.4% dividend yields, what makes these FTSE 100 and FTSE 250 high-yield heroes so special? Royston Wild…

Read more »